REGENXBIO Opens State-of-the-Art Gene Therapy Manufacturing Facility

In-house facility to produce NAV Technology-based AAV gene therapies at 2,000 liters scale $65 million invested in new facility, enabling end-to-end control of gene therapy manufacturing in Montgomery County, Maryland ROCKVILLE, Md., June 9, 2022 /PRNewswire/ — REGENXBIO Inc. (Nasdaq:…

Click here to view original post